Natulan (Procarbazine Hydrochloride)

Procarbazine hydrochloride, the active ingredient in Natulan, is an alkylating agent presented as an oral dosage form for oral use. It is employed in the treatment of Hodgkin lymphoma, brain tumors and other malignant neoplasms. GNH USA supplies Natulan as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Natulan, an alkylating antineoplastic agent, is indicated for several malignant disease categories. - Hodgkin lymphoma: contributes to disease remission when used as part of combination chemotherapy. - Brain tumors: provides cytotoxic activity against certain primary and metastatic brain neoplasms. - Other malignant neoplasms: used in selected solid tumours and hematologic cancers as part of multi‑drug regimens.

Adverse reactions may occur with Natulan therapy.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Fatigue: generalized tiredness. - Loss of appetite: reduced desire to eat. - Mild leukopenia: slight decrease in white blood cells. - Alopecia: temporary hair thinning. - Vomiting: occasional episodes.

Serious or Rare Side Effects: - Severe bone‑marrow suppression: profound pancytopenia. - Secondary malignancies: risk of therapy‑related cancers. - Hepatotoxicity: significant liver enzyme elevation. - Hypersensitivity reactions: rash, fever, or anaphylaxis. - Neurotoxicity: peripheral neuropathy or seizures. - Severe infections: opportunistic bacterial or fungal infections.

Careful monitoring and patient counseling are essential when using Natulan. - Blood count monitoring: perform regular CBC to detect leukopenia or anemia. - Liver function assessment: check hepatic enzymes before and during therapy. - MAO inhibitor avoidance: do not co‑administer with monoamine oxidase inhibitors. - Hypersensitivity vigilance: discontinue if severe allergic reaction occurs. - Elderly caution: dose adjustments may be needed for older patients. - Store at below 25°C: keep in the original pack, protect from moisture.

Drug interaction assessment should be performed prior to initiating Natulan.

Major Interactions (Avoid): - MAO inhibitors: concurrent use can cause hypertensive crises. - Live vaccines: increased risk of infection due to immunosuppression. - Certain antidepressants (e.g., SSRIs): may potentiate serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP450 substrates: procarbazine may alter metabolism of drugs processed by CYP1A2. - Antiepileptic agents: may require dose adjustments. - Other alkylating agents: additive bone‑marrow toxicity may occur.